Genomic Health, Inc. (NASDAQ:GHDX)

it was featured. i read the 8k. they develop tests. they will present at a meeting in May. Soon. I am hoping for good news. Cancer is starting to yield to better treatments and early detection.

Keep changing my mind on this one. The bull case is they do a good job working with health plans and community oncologists and I think they can leverage those skills to sell product .

guy on dip

A single treatment won't work for everyone, so there's definite promise in a company working to perfect tests so that individualized treatments may be prescribed. This would result in less frustration for the patient and his/her family and, hopefully, better survival rates.

Genomics will continue to play a bigger role in the future of medicine and treatments.

Strong insider buys & strength of colon/protate cancer tests could eliminate chemo. Long

There is no more important health issue than getting treatments right in the fight against cancer and GHDX has the best if those tools right now. I expect their research to continue and that should them keep them in a leadership position.

This is the future of medicine--custom treatment. Genomic Health may or may not be a winner, but I'm willing to bet some CAPS points to follow the story.

I'd love to get it a little cheaper, but I think it can outperform over 5-10 years from here.

A whole new way to diagnose that has to catch on. With limited competition, this company will do well.

Sitting near 52 week low. It won't last. Wish I had more real $$ to invest in this one at the moment.

Aging population, more and more cancer. Might as well make some money off it.

Revenue increasing at a very nice clip, about to climb out of the red and into profitability, nice cash cushion. Life science sounds sexy.

Genomics is a promising direction for genetic studies.

GHDX

fransgeraedts pick

Oncotype DX revenues for the last four quarters were 26, 28, 31 and 34 million respectively. The assay was also recently shown to be predictive of distant recurrence in colon cancer, although the market was apparently disappointed by its inability to predict the effectiveness of chemotherapy as it does in breast cancer. The company remains unprofitable as they aggressively pursue expanded indications for the Oncotype DX assay, but the burn rate is well controlled with a cash position that will carry them safely at least through the end of 2010 without dilution. Due to their reliance on a single product and lack of a clear pipeline, GH has an inherently weaker risk/reward profile when compared to Myriad. However, their current share price represents an attractive entry point given that they were at 27 a month ago without any change in fundamentals.

Mmm...medical tests...

This company allows for targeted treatment of breast cancer. By better determining patients that will benefit from chemotherapy, there are substantial benefits for the patient and for the payors.